Back to Results
First PageMeta Content
Immunology / Glatiramer acetate / Lipoatrophy / Teva Pharmaceutical Industries / Food and Drug Administration / Natalizumab / Multiple sclerosis / Pharmacology / Health


Copaxone Warning Letter OPDP
Add to Reading List

Open Document

File Size: 172,22 KB

Share Result on Facebook

City

Kansas City / Reference / /

Company

Larry Downey Teva Neuroscience Inc / Teva Neuroscience Inc. / MBA / Teva Pharmaceutical Industries / /

Event

FDA Phase / /

/

IndustryTerm

energy / /

MedicalCondition

anaphylaxis/hypersensitivity / clinically definite multiple sclerosis / leg and optic neuritis / chest pain / numbness / fatigue / multiple sclerosis / hypersensitivity / MS / pruritus / Against Multiple Sclerosis / influenza / disease / dyspnea / pulmonary function / erythema / skin necrosis / seizure / pain / Relapsing-Remitting Multiple Sclerosis / urticaria / infection / inflammation / rash / immunosuppression/infections / fibrosis / /

MedicalTreatment

immunosuppression / /

Organization

Division of Direct-to-Consumer Promotion / Food and Drug Administration / Division of Professional Promotion / Division of Drug Marketing / Advertising / and Communications / office of Prescription Drug Promotion / MBA Director Office / Team COPAXONE® / U.S. Food and Drug Administration / Center for Drug Evaluation and Research / DEPARTMENT OF HEALTH / /

Person

Silver Spring / THOMAS W ABRAMS / Thomas W. Abrams / David was / David Kyle / Karen Stewart / /

Position

energetic and dynamic athlete / neurologist / Executive Vice President / US Branded Pharmaceuticals Teva Pharmaceuticals / registered nurse / nurse / /

Product

mannitol / COPAXONE / MA / COPAXONE® / /

ProvinceOrState

Maryland / Missouri / Mississippi / /

Technology

MRI / /

URL

http /

SocialTag